Table 1.
Longitudinal model‐predicted percentage of PASI75 responders for systemic treatment in patients with moderate to severe psoriasis at 4 and 12 weeks
| Drug | Clinical dose | ET50 (Week) | ET90 (Week) | PASI75 (%) | |
|---|---|---|---|---|---|
| Week 4 | Week 12 | ||||
| TNF‐α inhibitor | |||||
| Adalimumab | 40 mg Q2W | 6.0 (4.6, 7.8) | 11.7 (8.5, 16.1) | 15.6 (5.15, 30.2) | 65.9 (53.6, 76.8) |
| Certolizumaba | 200 mg Q2W | 4.2 (2.8, 6.0) | 9.9 (6.5, 14.3) | 38.8 (21.7, 59.4) | 74.5 (62.2, 84.1) |
| Etanercept | 25 mg BIW | 8.2 (6.3, 10.8) | 16.4 (12.3, 20.8) | 4.64 (0.00, 10.7) | 32.0 (20.7, 44.0) |
| Etanercept | 50 mg BIW | 7.7 (6.1, 9.9) | 14.6 (11.8, 19.0) | 6.87 (1.08, 15.7) | 48.7 (34.2, 60.6) |
| Infliximab | 5 mg/kg Q8W | 4.7 (3.5, 6.2) | 10.0 (6.8, 14.2) | 32.7 (16.0, 51.5) | 75.3 (62.6, 85.8) |
| IL‐17 inhibitor | |||||
| Brodalumaba | 210 mg Q2W | 3.9 (2.8, 5.3) | 9.2 (6.1, 13.1) | 46.9 (27.1, 66.7) | 80.2 (69.0, 89.2) |
| Ixekizumab | 80 mg Q4W | 3.7 (2.6, 5.3) | 8.9 (5.7, 13.1) | 48.8 (29.4, 68.6) | 81.7 (71.7, 90.7) |
| Secukinumab | 150 mg QM | 5.5 (4.1, 7.1) | 11.0 (7.7, 15.3) | 21.5 (8.86, 37.7) | 69.2 (57.0, 79.5) |
| IL‐12/23 inhibitor | |||||
| Briakinumabb | 100 mg Q4W | 5.8 (4.7, 7.0) | 10.9 (8.8, 13.6) | 19.0 (7.13, 34.8) | 78.4 (67.2, 87.9) |
| Ustekinumab | 45 mg Q12W | 7.1 (5.8, 8.7) | 13.3 (11.1, 16.7) | 10.2 (3.01, 21.6) | 65.2 (51.9, 76.4) |
| Dihydrofolate reductase inhibitor | |||||
| Methotrexate | 18 mg QW | 9.2 (7.3, 11.5) | 18.7 (15.3, 21.6) | 3.38 (0.000, 8.61) | 28.5 (17.0, 40.0) |
| JAK inhibitor | |||||
| Tofacitiniba | 5 mg BID | 6.9 (5.0, 9.6) | 14.3 (9.4, 20.1) | 9.21 (1.85, 19.4) | 40.8 (28.2, 52.5) |
| Tofacitiniba | 10 mg BID | 6.0 (4.5, 8.1) | 12.2 (8.4, 17.5) | 16.9 (6.23, 32.8) | 60.7 (48.1, 72.5) |
| Baricitiniba | 10 mg QD | NA | NA | NA | NA |
| Vitamin A analog | |||||
| Acitretin | 30 mg QD | NA | NA | NA | NA |
| CD2 antagonist | |||||
| Alefacept | 10 mg QW | 11.1 (9.0, 13.9) | >24c (23.5, NA) | 1.99 (0.000, 6.20) | 15.6 (7.09, 24.1) |
| PDE4 inhibitor | |||||
| Apremilast | 30 mg BID | 7.4 (5.4, 10.2) | 15.1 (10.2, 20.7) | 5.66 (0.345, 12.7) | 28.5 (17.9, 39.8) |
| Calcineurin inhibitor | |||||
| Ciclosporin | 2.5–5 mg/kg/d | NA | NA | NA | NA |
Values presented are mean (90% confidence intervals) and were generated assuming a typical weight of 90 kg.
Investigational.
Discontinued. All other drugs are approved.
Alefacept data only reported up to 24 weeks; ET90 is estimated to occur sometime beyond the time period for which there were reported data.
BID, twice daily; BIW, twice weekly; CD2, T lymphocyte; ET50, time to reach 50% of the maximal treatment effect; ET90, time to reach 90% of the maximal treatment effect; IL, interleukin; JAK, Janus kinase; NA, not available; PASI75, ≥ 75% reduction from baseline Psoriasis Area and Severity Index score; PDE4, phosphodiesterase 4; QD, once daily; QM, once monthly; QW, once weekly; Q2W, once every 2 weeks; Q4W, once every 4 weeks; Q8W, once every 8 weeks; Q12W, once every 12 weeks; TNF, tumor necrosis factor.